RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

about

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q47797184

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@en

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@nl

type

Item

label

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@en

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@nl

prefLabel

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@en

RSK2 is a new Pim2 target with ...... sitive acute myeloid leukemia.

@nl

P1476

RSK2 is a new Pim2 target with ...... ositive acute myeloid leukemia

@en

P2093

A S Green

http://www.w3.org/2001/XMLSchema#string

C Larrue

http://www.w3.org/2001/XMLSchema#string

C Récher

http://www.w3.org/2001/XMLSchema#string

D Bouscary

http://www.w3.org/2001/XMLSchema#string

E Saland

http://www.w3.org/2001/XMLSchema#string

E-F Gautier

http://www.w3.org/2001/XMLSchema#string

F Mazed

http://www.w3.org/2001/XMLSchema#string

J Decroocq

http://www.w3.org/2001/XMLSchema#string

J Mondesir

http://www.w3.org/2001/XMLSchema#string

J-E Sarry

http://www.w3.org/2001/XMLSchema#string

P2860

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Secondary mutations as mediators of resistance to targeted therapy in leukemia

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

2016 update of the PRIDE database and its related tools

Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

P2888

leu.2017.284

P304

597-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.284

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28914261

http://www.w3.org/2001/XMLSchema#string